Compare Transocean Ltd (RIG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs GeneDx Holdings Corp — how do they compare? Transocean Ltd trades at $5.3 (market cap $5.80B), while GeneDx Holdings Corp trades at $62.68 (market cap $1.83B). The key difference: Transocean Ltd is far larger — about 3.2× GeneDx Holdings Corp's market cap, and Transocean Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| RIG | WGS | |
|---|---|---|
Market Cap | $5.80B | $1.83B |
Sector | Technology | Technology |
52-Week High | $7.58 | $167.51 |
52-Week Low | $2.80 | $34.51 |
Enterprise Value | $10.74B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean Ltd. (RIG) trades at $5.02, down 2.33% today, reflecting ongoing investor caution despite recent contract wins. The stock shows a bearish technical bias with moving averages signaling sell pressure, while fundamentals reveal persistent net losses (-$2.92B in 2025) despite high gross margins (84.88%). Recent news highlights a $1B+ Equinor contract and pending Valaris merger, boosting long-term revenue visibility but failing to offset near-term profitability concerns.
RIG's investment case hinges on backlog execution and merger synergies, offering potential upside to the $7.00 consensus target. However, high leverage, volatile oil prices, and consecutive earnings misses pose significant risks. Analyst sentiment is divided (39% Buy, 39% Hold), suggesting cautious optimism amid operational challenges.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
